341 related articles for article (PubMed ID: 18928173)
1. [Chronic inflammation, oxidative stress and effects of erythropoetin in end-stage renal disease patients].
Lazarević T; Stojimirović B; Poskurica M; Lazarević M; Mitrović N; Stolić R
Med Pregl; 2007; 60 Suppl 2():109-13. PubMed ID: 18928173
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
3. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
[TBL] [Abstract][Full Text] [Related]
4. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.
Locatelli F; Andrulli S; Memoli B; Maffei C; Del Vecchio L; Aterini S; De Simone W; Mandalari A; Brunori G; Amato M; Cianciaruso B; Zoccali C
Nephrol Dial Transplant; 2006 Apr; 21(4):991-8. PubMed ID: 16384825
[TBL] [Abstract][Full Text] [Related]
5. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
6. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
9. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
Merta M; Sobotová D; Zahálková J; Bitterová Z; Jirka T; Knetl P; Kopenec J; Suchanová J; Vlasák J
Sb Lek; 2001; 102(1):41-52. PubMed ID: 11830918
[TBL] [Abstract][Full Text] [Related]
10. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
Abe M; Okada K; Soma M; Matsumoto K
Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
[TBL] [Abstract][Full Text] [Related]
11. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
13. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease.
Wagner M; Alam A; Zimmermann J; Rauh K; Koljaja-Batzner A; Raff U; Wanner C; Schramm L
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1573-9. PubMed ID: 21734083
[TBL] [Abstract][Full Text] [Related]
14. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
15. [Inflammation and nutritional status in haemodialysis patients].
Tirmenstajn-Janković B; Dimković N; Zivanović M
Med Pregl; 2007; 60 Suppl 2():137-41. PubMed ID: 18928180
[TBL] [Abstract][Full Text] [Related]
16. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients.
Schiffl H; Lang SM
Nephrol Dial Transplant; 2006 Jan; 21(1):133-7. PubMed ID: 16144854
[TBL] [Abstract][Full Text] [Related]
17. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
18. Outcome data on pediatric dialysis patients from the end-stage renal disease clinical indicators project.
Brem AS; Lambert C; Hill C; Kitsen J; Shemin DG
Am J Kidney Dis; 2000 Aug; 36(2):310-7. PubMed ID: 10922309
[TBL] [Abstract][Full Text] [Related]
19. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy.
Sirken G; Kung SC; Raja R
ASAIO J; 2003; 49(4):422-5. PubMed ID: 12918584
[TBL] [Abstract][Full Text] [Related]
20. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
